The differential response of HER2+ tumours to T-DM1 was reported in Phase III KATHERINE trial of adjuvant T-DM1 versus Trastuzumab for residual invasive disease after neoadjuvant therapy for HER2 + BC. This evidence concerns the gene ERBB2 and neoplasm.